Keratitis News and Research

RSS
NanoViricides retires Series C Convertible Preferred Stock previously purchased by Seaside

NanoViricides retires Series C Convertible Preferred Stock previously purchased by Seaside

Sucampo's RESCULA 0.15% now available by prescription across the U.S.

Sucampo's RESCULA 0.15% now available by prescription across the U.S.

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

Daily lenses vary in ocular response, adverse effects

Daily lenses vary in ocular response, adverse effects

Johnson & Johnson Vision Care develops new educational resource

Johnson & Johnson Vision Care develops new educational resource

IMDx HSV-1/2 for Abbott m2000 assay receives CE-marking

IMDx HSV-1/2 for Abbott m2000 assay receives CE-marking

Killer coating destroys bacteria and fungi on contact

Killer coating destroys bacteria and fungi on contact

Dompé enters definitive agreement to acquire Anabasis

Dompé enters definitive agreement to acquire Anabasis

Aganirsen demonstrates significant activity in two models of wet AMD, ischemic retinopathy

Aganirsen demonstrates significant activity in two models of wet AMD, ischemic retinopathy

Study shows stalled growth in extended-wear lens prescribing

Study shows stalled growth in extended-wear lens prescribing

Study examines prevalence of Fusarium in bathroom sink drains

Study examines prevalence of Fusarium in bathroom sink drains

RegeneRx to initiate enrollment in RGN-259 Phase 2 trial for dry eye syndrome

RegeneRx to initiate enrollment in RGN-259 Phase 2 trial for dry eye syndrome

Anabasis, Scil Proteins enter license deal for rhNGF to treat eye diseases

Anabasis, Scil Proteins enter license deal for rhNGF to treat eye diseases

Scientists develop new software to test alterations in night vision

Scientists develop new software to test alterations in night vision

Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease

Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease

Questcor's H.P. Acthar Gel sNDA for infantile spasms receives FDA approval

Questcor's H.P. Acthar Gel sNDA for infantile spasms receives FDA approval

NanoViricides files financial year end annual report with SEC

NanoViricides files financial year end annual report with SEC

Researchers develop infected tissue model for Aganocide compounds

Researchers develop infected tissue model for Aganocide compounds

Study reveals how galectin-3 carbohydrate-binding protein promotes angiogenesis

Study reveals how galectin-3 carbohydrate-binding protein promotes angiogenesis

Scientists discover weakness of human louse

Scientists discover weakness of human louse